<div id="readability-page-1"><div>TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Theravance Biopharma, Inc. (“Theravance” or “the Company”) (NASDAQ: TBPH) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Theravance reported spending millions of dollars on operations expenses while its CYPRESS trial was in the enrollment phase, representing a major cash burn on a high-risk program. The Company’s trial ultimately failed. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA0MDIyNTEwNTdyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA0MDIyNTEwNTdyMQ"/> The Schall Law Firm Brian Schall, Esq. 310-301-3335 info@schallfirm.com www.schallfirm.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260402251057/en/</div></div>

Theravance生物制藥

Schall 律師事務所正在代表 Theravance Biopharma, Inc.（納斯達克股票代碼：TBPH）的投資者調查潛在的證券法違規行為。調查的重點是該公司是否發佈了虛假或誤導性聲明，並未披露關鍵信息。據報道，Theravance 在其 CYPRESS 試驗中產生了重大運營費用，而該試驗最終失敗。遭受損失的股東被鼓勵參與調查，並可以聯繫 Schall 律師事務所以獲取更多信息

Theravance 生物製藥公司的投資者有機會與 Schall 律師事務所合作，參與該公司的欺詐調查